GC's Hunterase, a treatment for Hunter syndrome, has finally obtained full approval, 11 years after receiving conditional approval, the company said on Friday. After being designated as an orphan drug in September 2011, Hunterase, the world's second treatment for Hunter syndrome, received conditiona
Lunit said its chest X-ray AI imaging analysis solution, Lunit INSIGHT CXR, will be covered by national health insurance in Korea from as early as March 2024 because it has been designated as an innovative medical technology by the Ministry of Health and Welfare through the "Integrated Review and Ev
Y-Biologics, an antibody-drug development platform company, held a press briefing in Yeouido, Seoul, Thursday, ahead of its initial public offering (IPO) on the Kosdaq market and announced its plans to continue developing antibody drug development through funds secured by the IPO.In the upcoming lis
Korean physicians treat more patients per capita than any other OECD country, a recent report revealed.According to the "Health at a Glance 2023" published by the Organisation for Economic Co-operation and Development (OECD), a Korean doctor saw an average of 6,113 patients annually in 2021, the hig
PCL, a local diagnostic kit manufacturer, said it has signed a stock acquisition agreement with the global alternative investment group GEM (Global Emerging Markets) Group to enter the in vitro diagnostic medical device (IVD) markets in North America and Europe.GEM, headquartered in New York, the U.
Researchers from Korea Basic Science Institute (KBSI) and Hanyang University have developed a high-sensitivity rapid diagnostic paper slip chip that can effectively detect C-reactive protein (CRP) using non-invasive methods such as saliva and human blood.CRP is a representative acute phase reactive
Daewoong Pharma said it has signed a comprehensive memorandum of understanding (MOU) with China Meheco International, a Chinese pharmaceutical import and export company, to export Daewoong's treatment to China.Daewoong expects that through this MOU, the company will be able to accelerate the entry o
Lunit said it plans to supply Lunit INSIGHT CXR, its AI chest screening solution, to five major hospitals in Saudi Arabia.Lunit Insight CXR is software that utilizes AI-based technology to assist medical professionals by reading 10 chest diseases, such as lung nodules, lung hardening, and pneumothor
VUNO said it has signed a memorandum of understanding (MOU) with Readycure, a dementia treatment medical device company based in Korea, to jointly research artificial intelligence (AI) medical solutions and develop medical devices for dementia treatment.Under the MOU, both companies plan to develop
The following article has been provided by Vetter Pharma International GmbH as part of its public relations activities. Korea Biomedical Review has no relationship with and bears no responsibility for the contents and opinions in it. – Ed.Due to growing demand for specialized treatments and increasi
A research team at Seoul St. Mary's Hospital has presented a new direction for the treatment of acute and chronic graft-versus-host disease (GVHD), which occurs after allogeneic hematopoietic stem cell transplantation.Allogeneic hematopoietic stem cell transplantation is a primary method for treatin
Celltrion Group said the exercise amount for the share buy-back related to the appraisal right for the merger of Celltrion and Celltrion Healthcare totaled 7.9 billion won ($5.9 million) combined for both companies.The shares tallied due to the appraisal right were approximately 41,972 shares (about
GC said it has signed a contract manufacturing organization (CMO) contract for Euvichol, an oral cholera vaccine developed by EuBiologics Co.Under the agreement, GC will be responsible for the contract manufacturing of the finished drug product (DP) of Euvichol until 2026. The two companies also set
Bayer, a prominent player in the pharmaceutical industry, is establishing itself as a trailblazer in radiology, as shown by its commitment and strategic moves aimed at driving innovation in medical imaging.With a robust performance, generating close to 2 billion euros ($2.1 billion) in sales from ra
Despite a surge in sales of non-Covid-19 products, Seegene, which saw sales spike over a trillion won during the Covid-19 pandemic, continued to report an operating loss in the third quarter of this year.According to a public filing by the company last Friday, Seegene posted sales of 91.8 billion wo
Celltrion said it confirmed the bioequivalence of CT-P39, a biosimilar referencing Xolair (ingredient: omalizumab), compared to the original drug through a global phase 3 clinical trial.The company presented the results during the American College of Allergy, Asthma and Immunology (ACAAI) 2023, held
The global medical community is abuzz with anticipation as the first gene-editing therapy nears potential FDA approval in December.According to industry watchers, the gene-editing therapy Exa-cel, co-developed by CRISPR Therapeutics and Vertex Pharmaceuticals, is nearing potential FDA approval in De
Korea University Medical Center (KUMC) said that Korea University Anam Hospital (KUAH) has successfully secured the project for enhancing the internal medicine department at the National Pediatric Hospital Cambodia project, sponsored by the Korea International Cooperation Agency (KOICA).The project,
SK biopharmaceuticals said the U.S. patent protection for its epilepsy drug Xcopri (ingredient: cenobamate) has been extended for five years until October 30, 2032.Xcopri acquired a substance patent in Oct. 2007 and received new drug approval in the U.S. in Nov. 2019, with the drug officially being
Medytox won a lawsuit against the Ministry of Food and Drug Safety (MFDS) in a three-year battle over the product approval cancellation of its Meditoxin lineup, its botulinum toxin (BTX) product, for alleged use of unauthorized raw materials.According to Medytox, the Daejeon District Court ruled in